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Avascular, hypoxic retina has been postulated to be a
source of angiogenic factors that cause aberrant an-
giogenesis and intravitreal neovascularization (IVNV)
in retinopathy of prematurity. Vascular endothelial
growth factor (VEGF) is an important factor involved.
However, VEGF is also required for normal retinal
vascular development, which raises concerns about
inhibiting its activity to treat IVNV in retinopathy of
prematurity. Therefore, understanding the effects
that VEGF has on other factors in the development of
avascular retina is important to prevent aberrant an-
giogenesis and IVNV. Here, we show that STAT3 was
activated by increased retinal VEGF in the rat 50/10
oxygen-induced retinopathy model. Phospho-STAT3
colocalized with glutamine synthetase-labeled Müller
cells. Inhibition of STAT3 reduced avascular retina
and increased retinal erythropoietin (Epo) expres-
sion. Epo administered exogenously also reduced
avascular retina in the model. In an in vitro study,
hypoxia-induced VEGF inhibited Epo gene expres-
sion by STAT3 activation in rat Müller cells. The mech-
anism by which activated STAT3 regulated Epo was by
inhibition of Epo promoter activity. Together, these
findings show that increased retinal VEGF contributes
to avascular retina by regulating retinal Epo expression
through Janus kinase/STAT signaling. Our results sug-
gest that rescuing Epo expression in the retina before
the development of IVNV may promote normal devel-
opmental angiogenesis and, therefore, reduce the stim-
ulus for later pathologic IVNV. (Am J Pathol 2012, 180:
1243–1253; DOI: 10.1016/j.ajpath.2011.11.031)Retinopathy of prematurity (ROP) is a leading cause of
childhood blindness.1 It is characterized first by a delay
in developmental retinal angiogenesis and potentially
some capillary constriction, resulting in the clinical ap-
pearance of avascular retina and then later by dilated
and tortuous retinal vessels and intravitreous neovascu-
larization (IVNV), that is, blood vessels that proliferate into
the vitreous. Several clinical studies have found an asso-
ciation between large areas of peripheral avascular retina
and worse outcomes in ROP.2,3 Besides ROP, prolifera-
tive, uncontrolled angiogenesis occurs as a result of
avascular retina in other conditions, including prolifera-
tive diabetic retinopathy and retinal vein occlusions.4
Currently, efforts have been focused on inhibiting aber-
rant angiogenesis in these conditions5,6 and less on re-
ducing avascular retina,7 the causes of which are incom-
pletely understood.8–13 In this study, we seek to
understand the causes and mechanisms for avascular
retina in retinal diseases with IVNV. We report our find-
ings with the use of a model developed by Penn et al,14
in which newborn rat pups are exposed to fluctuations in
oxygen levels between 50% and 10%, yielding arterial
oxygen concentrations similar to transcutaneous oxygen
levels reported in human severe ROP.14,15 The model
also produces a characteristic appearance of severe
ROP with peripheral avascular retina similar to zone II
ROP,14,16 followed by retinal tortuosity,17 and then IVNV
at the junctions of vascular and avascular retina, similar
to stage 3 ROP.16,18 With the use of this model, we found
that vascular endothelial growth factor (VEGF), one of the
most notable angiogenic factors that causes aberrant
retinal angiogenesis,19,20 was significantly increased in
retinas from pups with avascular retina, compared with
retinas from age-matched pups raised in room air that
had full vascularization of the inner retinal plexus.21
Therefore, a question was raised whether the increase in
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Janus kinase (JAK)/STAT signaling pathway is a main
signaling mechanism for cytokines and growth factor re-
ceptors. Activation of JAK/STAT signaling involves ligand
binding and dimerization of cell membrane receptors,
which result in the activation of receptor-associated JAKs
and phosphorylation of receptors at cytoplasmic tyrosine
residues. STATs dock on these phosphotyrosine motifs
by their Src homology 2 domains. Receptor-bound
STATs then are phosphorylated on conserved carboxy-
terminal tyrosines and then dimerize. Dimerized STATs
translocate into the nucleus to regulate gene transcri-
ption,22 resulting in cell proliferation, differentiation, migra-
tion, and apoptosis. The regulatory mechanism of STATs on
target genes requires DNA binding and coactivator or
corepressor recruitment. The transcriptional activity of
STATs is potentiated by phosphorylation of a conserved
carboxy-terminal serine residue, which increases interac-
tions with coactivators or corepressors. Therefore, JAK/
STAT signaling can lead to increased or reduced tran-
scription of a gene. Besides being activated by a
cytokine or interferon, JAK/STAT signaling can be trig-
gered by hypoxia and reactive oxygen species. Down-
stream effects can include regulation of angiogenic
genes such as VEGF and hypoxia inducible factor-1 .23
We previously reported that activation of JAK2 and
STAT3 signaling exacerbated the severity of retinopathy
in a model of oxygen-induced retinopathy (OIR) rescued
in supplemental oxygen.24
In this study, we hypothesized that activation of STATs
would contribute to the persistence of avascular retina
after repeated oxygen fluctuations by promoting apopto-
sis or inhibiting angiogenic factor expression. We found
that the angiogenic cytokine, erythropoietin (Epo), was
down-regulated by VEGF-mediated STAT3 activation and
was involved in the persistence of avascular retina. We
tested our hypothesis with both in vitro cell cultures and
the relevant 50/10 OIR model.
Materials and Methods
Animals
All animal procedures were conducted in accordance
with the University of Utah and University of North Caro-
lina (Guide for the Care and Use of Laboratory Animals)
and the Association for Research in Vision and Ophthal-
mology Statement for the Use of Animals in Ophthalmic
and Vision Research.
Rat 50/10 OIR Model
A bioactive gas controller (Oxycycler; BioSpherix, New
York, NY) that regulates the atmosphere inside an incu-
bator by injecting either nitrogen or oxygen was used to
induce OIR in newborn Sprague-Dawley rats (Charles
River, Wilmington, MA), as previously reported.14 Within 4
hours of birth, pups and their mothers were placed into
the incubator, which cycled oxygen between 50% and
10% every 24 hours for 14 days. Carbon dioxide in cham-bers was monitored and flushed from the system by
maintaining sufficient gas flow and using soda lime. Litter
numbers were maintained between 12 and 14 pups for
each experiment to assure consistency in outcomes, all
animals were weighed, and mean body weight of litters
was found to be within 2 g of each other at the time of
treatment.
Animals Treated with AG490 or Erythropoietin
or Neutralizing VEGF Antibody
AG490 (LC Laboratories, Woburn, MA) is a synthetic
protein tyrosine kinase inhibitor that inhibits JAK225 and
was used to inhibit the JAK/STAT pathway in rats.26 To
test whether JAK2/STAT3 inhibition affects angiogenesis
and ultimately leads to avascular retina in the 50/10 OIR
model rat, pups were treated with 10 mg/kg AG490 in 5%
dimethyl sulfoxide (DMSO; MP Biomedicals, Solon, OH)
in PBS (Sigma-Aldrich, St. Louis, MO) by i.p. injection.
This dose was based on earlier studies that showed an
inhibitory effect on IVNV in the 50/10 OIR model rescued
in room air.24 Intraperiotneal injections were administered
daily from postnatal day (p) 3 to p13. Control animals
received i.p. injections of sterile 5% DMSO in PBS. Sep-
arate litters received i.p. injections of Epo (human Procrit;
41.6 g/kg; R&D Systems, Minneapolis, MN) or PBS con-
trol at multiple time points (p2, p4, and p6). Before the
decision to use human Procrit, rat Epo was compared
with Procrit, and no difference was found in the resulting
measured hematologic parameters (data not shown).
Fifty nanograms of neutralizing VEGF antibody (recog-
nizes only VEGF164 splice variant) or control IgG (R&D
Systems) was delivered to one eye of pups raised in the
50/10 OIR model by intravitreous injection at p12. The
fellow eye was used as a noninjection control. All of the
injections were done during the 50% O2 cycle. Percent-
age of avascular retina, platelet counts in whole blood,
and interested proteins in whole retinas were measured
at p14. Pups were removed from cycling for 20 minutes
for treatments. Pup weights were obtained before each
treatment and the time of assay and were not found to be
significantly different between experimental and control
50/10 OIR groups.
Dissecting Retinal Tissue for Flatmounts and
Cryosections
Pups were anesthetized by i.p. injection of ketamine (20
mg/kg) and xylazine (6 mg/kg). Both eyes were enucle-
ated. For flatmounts, eyes were fixed in 4% paraformal-
dehyde (PFA) for 2 hours. Within the first 10 minutes,
anterior segments were removed, and retinas with intact
ora serratas were carefully dissected and placed into
PBS with care taken to remove the hyaloidal vessels and
any remaining vitreous. Then, each retina was placed
onto a microscope slide and flattened by making four
incisions, each 90° apart, beginning at the ora serrata
and extending centrally from the equator, stopping short
of the optic nerve opening.
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ing 10 mmol/L sodium orthovanadate for 10 minutes.
Anterior segments were removed, and retinas were
placed into 4% PFA that contained 10 mmol/L sodium
orthovanadate for another 15 minutes. Retinas were then
placed into 30% sucrose/PBS overnight. Each retina was
dried with filter paper, soaked in optimal cutting temper-
ature compound (Tissue Tek; product no. 4583; EMS,
Hatfield, PA), and kept at 80°C for future analysis. In
most analyses, one eye from each pup was used for
flatmount and the other for fresh tissue analysis.
Tissue Staining for Flatmounts
Flattened retinas were incubated in 4% PFA overnight at
4°C, then washed with 1 Tris buffer (50 mmol/L Trizma
Maleate, 50 mmol/L sodium hydroxide, pH 7.2; Sigma-
Aldrich) for three times. After the washes, retinas were
incubated with 1 Tris buffer/1% Triton X-100 for 15
minutes at room temperature, followed by three washes
with 1 Tris buffer. Retinas then were incubated with
ADPase staining solution (200 mmol/L Trizma Maleate,
pH 7.2, 3 mmol/L lead nitrate, 6 mmol/L magnesium chlo-
ride, 2 mmol/L ADPase; Sigma-Aldrich) for 15 to 25 min-
utes at 37°C. After rinsing in 1 Tris buffer three times,
retinas were then placed in ammonium sulfide (1:30 di-
luted in water; Fisher Scientific, Fair Lawn, NJ) for 1 to 2
minutes at room temperature, mounted in Fluoromount-G
(Southern Biotech, Birmingham, AL), and placed on
slides with coverslips. Images of the superficial blood
vessel layers were captured with an inverted microscope
(Olympus 1  81; Olympus, Tokyo, Japan) and digitally
stored for analysis. Image sections were stitched with the
commercial image management software (Photoshop
version 7.0; Adobe Systems, Mountain View, CA) and
assembled with methods that maintain the original im-
age dimensions and do not induce image distortion
(PhotoFit Premium version 1.44; TekMate Inc., Tokyo,
Japan; or Photoshop; Adobe Systems).
Tissue Staining for Cryosections
Retinas cut into 10-M sections were incubated in 20
g/mL proteinase K in TE buffer (pH 8.0) for 1.5 minutes,
washed with cold PBS, incubated with 5% goat serum/1
PBS for 1 minute, and then washed with cold PBS fol-
lowed by PBS/1% Triton X-100 three times. Sections were
incubated in 10% normal goat serum for 1 hour to block
nonspecific binding of the primary antibody. Mouse anti-
glutamine synthetase (GS; 1:2000; BD Transduction Lab-
oratories, Franklin Lakes, NJ) and rabbit anti-phosphory-
lated STAT3 (p-STAT3; Y705; 1:50; Cell Signaling
Technology Inc., Danvers, MA) were used, and the sec-
tions were incubated overnight at 4°C. After three washes
in PBS, sections were incubated for 1 hour with a 1:500
dilution of Alexa 594-conjugated goat anti-mouse sec-
ondary antibody (Invitrogen, Carlsbad, CA) for GS or
Alexa 488-conjugated goat anti-rabbit secondary anti-
body (Invitrogen) for p-STAT3. The sections were rinsed
in PBS and mounted in Fluoromount-G (Southern Bio-tech). Images were captured with an inverted micro-
scope (Olympus 1  81) and digitally stored for analysis.
Measurement of Avascular Areas
To measure avascular retinal areas, digitized retinal im-
age sections were assembled with methods that maintain
original image dimensions (PhotoFit Premium ver-
sion1.44; TekMate Inc.). Total retinal and summed pe-
ripheral avascular retinal27 areas were computed in pix-
els with Image Tool version 3 (University of Texas, San
Antonio, TX) and converted to mm2 (using a calibration
bar on each image). Avascular retinal areas were ex-
pressed as a percentage of total retinal area for each
eye. Measurements were performed by two independent
masked reviewers. A third reviewer was used to rectify
discrepancies in measurements, and a final consensus
was determined.
RNA Isolation and Analysis
Samples were removed from RNAlater, and total RNA
was extracted with the RNeasy Mini kit (Qiagen, Valencia,
CA). RNA was quantified by NanoDrop. cDNA was gen-
erated with the use of High Capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA). RT-PCR was per-
formed on an ABI Prism 7500 sequence detector (Ap-
plied Biosystems) with the use of TaqMan probes (Ap-
plied Biosystems). Expression levels for all genes were
normalized to the mean value of internal control GAPDH.
Protein Extraction and Western Blot Analysis
Retinal samples frozen in modified RIPA buffer (20
mmol/L Tris base, 120 mmol/L NaCl, 1% Triton X-100,
0.5% sodium deoxycholate, 0.1% SDS, 10% glycerol)
with protease cocktail inhibitor (1:100; Sigma-Aldrich)
and orthovanadate (1 mmol/L; Sigma-Aldrich) were ho-
mogenized and centrifuged at 13,000 rpm for 10 minutes
at 4°C. Total protein in the supernatant fluid was quanti-
fied by BCA Protein Assay (Pierce, Rockford, IL). Total
protein (50 g) for each sample was separated by
NuPAGE 4% to 12% Bis-Tris Gels (Invitrogen), trans-
ferred to a PVDF membrane, and incubated with primary
antibodies overnight at 4°C: p-STAT3, STAT3 (1:1000;
Cell Signaling Technology Inc.), active caspase 3 (1:
1000; Chemicon International, Temecula, CA), VEGF (all
splice variants), and erythropoietin (1:500; Santa Cruz
Biotechnology, Santa Cruz, CA). Membranes were
washed three times in Tris-buffered saline/0.1% Tween-
20, probed with horseradish peroxidase-linked second-
ary antibody, and visualized by enhanced chemilumines-
cence (Millipore Corp, Billerica, MA). All membranes
were reprobed with -actin (1:2000; Abcam, Cam-
bridge, MA) to ensure equal protein loading. Densitom-
etry analysis was done on exposed films with the use of
the software UN-SCAN-IT version 6.1 (Silk Scientific,
Orem, UT).
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The luciferase reporter vector Pluc-MCS was obtained
from Promega (Madison, WI). Plasmid Pluc-MCS-rEpo-
promoter was generated by ligating the sequences
from the rat Epo promoter (300 to 48) into the pluc-
MCS vector at the XhoI and HindIII sites. The integrity
of the plasmid construct was verified by the DNA se-
quencing (HSC Core Facility, The University of Utah,
Salt Lake City, UT).
Cell Culture and Transfections
Rat Müller cells (rMC-1s; kindly provided by V.P. Sarthy,
Northwestern University, Evanston, IL) were maintained
in DMEM/high glucose (1000 mg/L; Sigma-Aldrich) with
10% FBS. Cells were placed in an incubator (BioSpherix)
in hypoxia (1% oxygen) or in room air (21% oxygen) with
either Tryphostin AG490 (final concentration, 10 g/mL in
DMSO; LC Laboratories), human anti-VEGF165 antibody
(final concentration, 600 ng/mL in PBS; R&D Systems),
DMSO (control for AG490) or IgG (control for anti-
VEGF165). Six hours after treatment, cells were collected
for either Western blot analyses or real-time PCR for de-
tection of expression levels of p-STAT3, total STAT3, Epo,
and VEGF.
Transfections of Cos-7 cells were performed in 12-well
plates with a total amount of plasmid DNA of 0.7 g/well
with 0.75 L of JetPRIME (Polyplus-transfection Inc., New
York, NY). These DNA mixtures included Pluc-MCS (0.5
g) or Pluc-MCS-rEpo-Promoter (0.4 g), rat STAT3 ex-
pressing construct pExpress-1-rSTAT3 (0.2 g; Open
Biosystems; Lafayette, CO), and -galactosidase (0.1
g). Cells were treated with recombinant VEGF164 (20
ng/mL; R&D Systems), AG490 (10 g/mL), and VEGF
and AG490 together for 6 hours. Cells were collected for
luciferase and -galactosidase assay within 24 hours of
transfection.
ChIP Assay
Chromatin immunoprecipitation (ChIP) assays were per-
formed with a commercial reagent (Millipore Corp) ac-
cording to the manufacturer’s protocol. Briefly, rMCs
grown in 10-cm2 dishes were treated with control or with
AG490 (10 g/mL), VEGF (20 ng/mL), or both together
and placed into the hypoxia incubator at 1% O2 for 6
hours. Cells were grown in 21%O2 incubator as a control.
For the cross-linking step, an aliquot of formaldehyde
[37% (v/v)] was added directly to the culture medium to
achieve a final concentration of 1%, and the incubation
was done for 10 minutes. Cells were then rinsed twice
with cold PBS, harvested with cell scrapers, and lysed in
10 mL of an SDS buffer (1% SDS, 10 mmol/L EDTA, 50
mmol/L Tris, pH 8.1). The lysates were sonicated to shear
genomic DNAs to achieve lengths of between 200 and
1000 bp. The sheared lysates were centrifuged at 16,000
g for 10 minutes; supernatant fluids were collected and
diluted 10-fold with ChIP dilution buffer (24 mL of 0.01%
SDS, 1.1% Triton X-100, 1.2 mmol/L EDTA, 16.7 mmol/L
Tris-HCl, pH 8.1, 167 mmol/L NaCl) in the presence ofprotease inhibitors (Roche Diagnostics, Indianapolis, IN).
An aliquot (75 L) of a 50% slurry of salmon sperm
DNA-protein A-agarose was added and incubated for 30
minutes. Agarose beads were precipitated by brief cen-
trifugation, and the precleared supernatant fluid was col-
lected. Antibodies against STAT3 and control IgG anti-
body (Cell Signaling Technology Inc.) were added to this
2-mL supernatant fraction and incubated overnight at
4°C with gentle mixing. Sixty microliters of the salmon
sperm DNA-protein A-agarose slurry was added and in-
cubated for an additional 1 hour at 4°C. The antibody/
histone/DNA complex was collected by gentle centrifuge.
The presence of target DNA fragments was detected by
PCR after the DNA was de-cross-linked with proteins. The
primers used for rat Epo promoter were 5=-TGGCGAC-
CCCTCACGCACAC-3= and 5=-TCCCTAGCCTGTGAG-
TACTCAC-3=.
Statistical Analyses
Significant differences between groups were determined
by ANOVA with post hoc protected t-tests. A minimum P
value of 0.05 was considered statistically significant.
Results
STAT3 Is Activated in Retinas from Rat Pups
Raised in 50/10 OIR
We first determined whether the JAK/STAT signaling
pathway was activated in the retina after repeated fluc-
tuations in oxygen. At p14, pups raised in the 50/10 OIR
model show approximately 60% to 70% retinal vascular
coverage of the inner plexus and, therefore, have 30% to
40% avascular retinal area. However, pups raised in
room air have full vascularization of the inner plexus and,
therefore, no avascular retina (Figure 1A). Compared with
age-matched p14 pups raised in room air, retinal
p-STAT3 was significantly increased in retinas from pups
raised in the 50/10 OIR model (Figure 1, B and C),
whereas p-STAT1 and p-STAT5 were not changed (data
not shown). These results show that STAT3 activation is
associated with persistent avascular retina after repeated
fluctuations in oxygen in the 50/10 OIR model.
Inhibition of STAT3 Reduces Avascular Retina
Independent of Retinal VEGF and Active
Caspase 3
To investigate whether STAT3 activation led to the per-
sistence of avascular retina, pups raised in the 50/10
OIR model were administered a chemical inhibitor of
JAK/STAT signaling, AG490 (5 to 20 mg/kg), or control
PBS. On the basis of the inhibitory effects on STAT3
activation, we chose the 10-mg/kg dose of AG490 de-
livered as an i.p. injection (5 L/g of body weight) daily
from p3 to p13. Rat pups were sacrificed at p14, and
one eye was analyzed for retinal p-STAT3 and the other
for percentage of avascular retina. Retinal p-STAT3
was reduced in pups that received AG490 compared
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AG490 significantly reduced avascular retina com-
pared with control (Figure 2B), providing evidence that
JAK/STAT signaling contributed to avascular retina af-
ter repeated fluctuations in oxygen in the 50/10 OIR
model. There was no difference in body weight gain
between AG490 and control groups.
Next, we sought to determine the potential mecha-
nisms by which retinal STAT3 activation contributed to
avascular retina in the 50/10 OIR model. We initially
tested the effect of STAT3 activation on VEGF production,
because inhibition of VEGF could lead to reduced ret-
inal vascularization by inhibiting developmental angio-
genesis.28,29 However, no difference was observed in
retinal VEGF protein between AG490-treated and con-
trol pups (Figure 2C). In a previous study,11 we found
that pharmacologic inhibition of NADPH oxidase acti-
vation by apocynin reduced avascular retina and reti-
nal cleaved caspase 3, a downstream effector of both
the intrinsic and extrinsic pathways of apoptosis. In
addition, cleaved caspase 3 colabeled with NG2-pos-
itive pericytes and glial fibrillary acidic protein-positive
Müller cells in the inner nuclear layer. We postulated
that loss of these cells might interfere with normal ret-
inal vascular development and increase avascular ret-
ina by reducing endothelial cell support from pericytes
or from glial growth factor expression. We also found
evidence for direct endothelial cell apoptosis with co-
labeling of CD31 and cleaved caspase 3. We, there-
fore, asked whether JAK/STAT signaling contributed to
avascular retina in the 50/10 OIR model by triggering
apoptosis.22 We measured retinal cleaved caspase 3
and found no difference between AG490-treated and
Figure 1. Pups raised in 50/10 OIR model have increased avascular retina
and activation of retinal STAT3 at p14. A: Retinal vessels by flatmount with
ADPase staining in pups raised in room air and 50/10 OIR model (n  18).
B: Western blot analysis of STAT3 phosphorylation in retina from pups
raised in room air and 50/10 OIR. C: Quantification of Western gels shown
in panel B. **P  0.01 versus room air (ANOVA). Data shown in panels B
and C are representative of 12 independent samples. Results are means 
SEMs.control rat pups (Figure 2D).Inhibition of STAT3 Increases Retinal Epo
Expression
The data in Figure 2 do not support apoptosis or VEGF
expression as downstream events of activated STAT3-
mediated avascular retina. We, therefore, considered
other factors. Epo has been shown to be important in
stabilizing newly developed retinal vessels7 and has
been correlated with improved cognitive function later in
childhood.30 However, Epo has also been shown to
cause pathologic IVNV in OIR models,31 and, when used
to treat anemia of prematurity in human preterm infants,
Epo has been associated with more severe ROP.32 To
determine whether STAT3 activation mediated the ex-
pression of Epo in the retina, we measured retinal Epo
protein in pups raised in the 50/10 OIR model that had
been administered AG490 or control PBS. We found
AG490-treated pups had significantly increased retinal
Epo protein (Figure 3A) compared with control. Epo has
been reported as up-regulated in the liver and kidney in
other models of OIR33; therefore, we postulated that in-
creased Epo in other organs could enter the retinal or
choroidal circulation and be detected as increased in the
retina. To determine whether the increased Epo protein
was from retina rather than from systemic sources, we
also measured retinal Epo mRNA in pups raised in the
50/10 OIR model treated with AG490 or control. As shown
in Figure 3B, inhibition of STAT3 phosphorylation led to
greater retinal Epo mRNA expression compared with
control, similar to protein expression. We also tested the
effect of AG490 given as an i.p. injection on Epo expres-
sion in liver and kidney. We found no difference in liver
and kidney Epo mRNA and protein in pups treated with
AG490 compared with control (Figure 3, C and D). These
Figure 2. Decreased avascular retina with sustained retinal VEGF expres-
sion and caspase 3 activity in AG490-treated rat pups raised in the 50/10 OIR
model. A: Western blot analysis of p-STAT3 and total STAT3 in retina. **P 
0.01 versus PBS (ANOVA; n  8). B: Avascular retina analysis by measuring
the ratio of avascular area to total retina area with the use of an image tool.
*P  0.01 versus PBS (ANOVA; n  18). C and D: Western blot analyses
of retinal VEGF protein (C) and active caspase 3 (D). Data shown in
panels C and D are representative of 8 independent samples. Results are
means  SEMs.
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on retinal Epo expression.
Pups Administered Exogenous Epo Have
Reduced Avascular Retina
To determine whether the down-regulation of Epo medi-
ated by STAT3 activation in the retinas of pups raised in
the 50/10 OIR model contributed to increased avascular
retina, we administered pups exogenous Epo and mea-
sured the percentage of avascular retina. Pups raised in
the 50/10 OIR model were given i.p. Epo (41.6 g/kg or
5000 IU/kg) on days 2, 4, and 6. This dose of Epo was
sufficient to significantly increase blood platelet counts
compared with PBS control (Figure 4A). This dose was
also reported to cause plasma Epo levels similar to a
dose being tested in a clinical trial for neuroprotection34
in human preterm infants. At day 14, avascular retina was
significantly reduced in Epo-treated pups compared with
control (Figure 4B).
Figure 3. Increased retinal Epo expression in AG490-treated rat pups raised
in the 50/10 OIR model. A: Western blot analysis of Epo protein in retina.
**P  0.01 versus PBS (ANOVA; n  7). B: Retinal Epo mRNA analysis by
real-time PCR. **P  0.01 versus PBS (ANOVA; n  8). C: Western blot
analysis of Epo protein in liver and kidney (n  7). D: Real-time PCR of Epo
mRNA in liver and kidney (n  8). Results are means  SEMs.
Figure 4. Decreased avascular retina by exogenous Epo given at early time
points in the 50/10 OIR model. A: Platelet count of pups treated with Epo and
PBS injection exposed to the 50/10 OIR model. *P  0.05 versus PBS
(ANOVA; n  8). B: Analysis of avascular retina area. *P  0.05 versus PBS
(ANOVA; n  8). Results are means  SEMs.Retinal STAT3 Activation in Pups Raised in
50/10 OIR Is Inhibited by Intravitreous VEGF
Antibody
We previously found that repeated fluctuations in oxygen
significantly increased the expression of the pathologic
splice variant of VEGF, VEGF164, compared with a single
hypoxic episode.35 We, therefore, postulated that VEGF,
which was up-regulated in the 50/10 OIR model, might
trigger JAK/STAT signaling to locally regulate Epo ex-
pression. To test this, we administered a neutralizing
antibody to VEGF164 as an intravitreal injection at p12 to
one eye of pups raised in the 50/10 OIR model. The dose
and timing of the injection were previously found to sig-
nificantly reduce VEGF signaling and IVNV.13 Compared
with control nonimmune IgG injections in pups within the
same litters and to fellow noninjected eyes of pups from
both experimental and control groups, neutralizing VEGF
bioactivity with antibody significantly reduced phosphor-
ylation of STAT3 (Figure 5, A and B), providing support
that VEGF mediated STAT3 activation at p14 in the 50/10
OIR model.
Because retinal Epo expression was regulated by
STAT3 activity (Figure 3, A and B), we then measured
Epo protein in the same retinas of eyes treated with
anti-VEGF antibody or control IgG and found that local
retinal Epo was significantly increased in eyes treated
with the intravitreal-neutralizing antibody to VEGF (Figure
5, C and D). This supported the thinking that VEGF trig-
gered JAK/STAT signaling to reduce local Epo expres-
sion in the retina.
p-STAT3 Is Colocalized in Müller Cells in
Retinas of Pups Raised in the 50/10 OIR Model
The results above indicate that down-regulation of Epo by
Figure 5. Decreased STAT3 phosphorylation and increased Epo expression
in retinas of pups with VEGF-neutralizing antibody injection in the 50/10 OIR
model. A and B: Retinal p-STAT3 measured by Western blot analysis with
representative gels (A) and quantification of gels (B). Overall ANOVA, P 
0.001; post hoc Newman–Keuls multiple comparison testing: Vab versus Vab
non-Inj, **P  0.01, and Vab versus Vab IgG-Inj †††P  0.001 (n  6 to 8).
C and D: Retinal Epo protein by Western blot analysis with representative
gels (C) and quantification of gels (D). Overall ANOVA, P  0.01; post hoc
Newman–Keuls multiple comparison testing: Vab versus Vab non-Inj, **P 
0.01; Vab versus Vab IgG-Inj, ††P 0.001 (n 8). Results are means SEMs.
IgG Inj, IgG injection; IgG Non, IgG noninjection; Vab Inj, VEGF antibody
injection; Vab Non, VEGF antibody noninjection.VEGF-mediated STAT3 activation in the retina contributes
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retinal cryosections from eyes of pups raised in room air
or in the 50/10 OIR model for p-STAT3 at the tyrosine 705
site. p-STAT3 labeling was found mainly in the outer
plexiform layer in eyes from pups raised in room air and
in the 50/10 OIR model. Colabeling with the Müller cell
marker, GS (Figure 6A), was qualitatively greater in sec-
tions from the 50/10 OIR model than from pups raised in
room air (Figure 6A). Because p-STAT3 was localized to
Müller cells and the 50/10 OIR model caused retinal
hypoxia,36 we also tested whether Müller cells were hy-
poxic in the 50/10 OIR model. Pups were given an i.p.
injection of pimonidazole (Hypoxyprobe, HPI, Inc., Burl-
ington, MA [60 mg/kg], a marker for hypoxia, 90 minutes
before sacrifice. Retinal cryosections from eyes of rats
raised in the 50/10 OIR model were stained with GS and
Hypoxyprobe. Colabeling of Hypoxyprobe with the Müller
cell marker, GS, was seen in sections from the 50/10 OIR
model (Figure 6B).
STAT3 Is Activated by VEGF in Rat Müller Cells
To investigate the mechanisms involved in STAT3 activa-
tion in the 50/10 OIR model, we used a rat Müller cell line
(rMC-1). We initially tested the hypothesis that VEGF stim-
ulation would increase p-STAT3 and regulate Epo ex-
pression. Compared with control, p-STAT3 was signifi-
cantly increased in rMC-1 cells treated with VEGF (20
ng/mL) at both the tyrosine 705 (Figure 7, A and C) and
serine 727 (Figure 7, B and D) sites in a time-dependent
manner, peaking 5 minutes after VEGF treatment.Epo Is Down-Regulated by VEGF Stimulated
STAT3 Activation in Müller Cells
Our study with Hypoxyprobe staining showed that re-
peated fluctuations of oxygen in the 50/10 OIR model
caused retinal36 and Müller cell hypoxia (Figure 6B).
Therefore, we postulated that Epo gene expression was
regulated by hypoxia-induced VEGF-stimulated STAT3
activation in Müller cells. To test this prediction, rMC-1
cells were exposed to 21% or 1% O2 for 6 hours. As
shown in Figure 8A, compared with 21% O2, VegfamRNA
level was significantly increased in rMC-1 cells incubated
in 1%O2, and a parallel reduction in Epo gene expression
Figure 6. A: Increased p-STAT3 is localized in
retinal Müller cells of pups raised in the 50/10
OIR model compared with pups raised in room
air. Immunohistochemical labeling of cryosec-
tion that shows p-STAT3 colocalized with Müller
cells (arrows) in room air and 50/10 OIR, using
antibodies for p-STAT3 and Müller cell marker
GS. No primary antibody control sections show
mainly DAPI. Density of p-STAT3 colabeling
with GS was quantified by confocal colocaliza-
tion analysis and shows increased pSTAT3 in GS
colabeled cells in the 50/10 OIR model com-
pared with room air. GCL, ganglion cell layer;
INL, inner nuclear layer; IPL, inner plexiform
layer; ONL, outer nuclear layer; OPL, outer plex-
iform layer. Representative of three separate ex-
periments. B: Retinal Müller cells of pups raised
in the 50/10 OIR model at p18 are hypoxic as
shown by staining with antibody to GS and to
Hypoxyprobe.
Figure 7. STAT3 is activated by VEGF in rat Müller cells (rMC-1). Western
blot analysis of p-STAT3 at Tyr 705 (A and C) and Ser 727 (B and D), total
STAT3 and loading control -actin at different time points after VEGF (20
ng/mL) treatment (A and B). Representative quantification of gels (C and D).
Overall ANOVA. P  0.0001; post hoc Newman–Keuls multiple comparison
testing: ***P  0.001, **P  0.01, and *P  0.05 versus 0 minute of VEGF
treatment. Results are means SEMs (n 3). Data are representative of three
independent experiments.
1250 Wang et al
AJP March 2012, Vol. 180, No. 3was also seen (Figure 8B). The down-regulation of Epo in
1% O2 was prevented by AG490 or by treatment with a
neutralizing antibody to VEGF. However, in the presence
of both AG490 and VEGF antibody, Epo mRNA was sig-
nificantly elevated, twofold over control in 21% O2 and
was significantly increased compared with either AG490
and VEGF antibody treatment alone (Figure 8B). These
data support the postulate that hypoxia-inhibited Epo
gene expression was mediated by VEGF-induced STAT3
activation in rMC-1 cells and also suggested that parallel
signaling pathways could be involved in the regulation of
Epo gene expression in hypoxia when VEGF-mediated
STAT3 activation was inhibited.
STAT3 is a transcriptional factor. After activation,
STAT3 can enter the nucleus and regulate gene tran-
scription by directly binding to promoters of target genes.
A sequence TTCCCGAA within the 5= promoter region
(164 to 156) of the rat Epo gene shares similarities to
the consensus STAT3 binding motif: TTC(N)2–4GAA or
TT(N)4–6AA. To test the prediction that this potential
STAT3 binding site was involved in the transcription of the
Epo gene, we first determined whether STAT3 was capa-
ble of binding to this site within the promoter of the Epo
gene with the use of a ChIP assay. PCR quantification of
the ChIP assay showed that rMC-1 cells cultured in 1%
O2 induced STAT3 recruitment to the promoter of the Epo
gene (Figure 8C). However, in the presence of AG490 or
VEGF antibody, hypoxia-induced p-STAT3 recruitment to
the Epo promoter was significantly reduced compared
Figure 8. Activated STAT3 by hypoxia-induced VEGF suppresses Epo gene
transcription by a STAT3 binding site within Epo promoter in rMC-1 cells. A
and B: Real-time PCR of vegfa mRNA (A) and Epo mRNA (B) in rMC-1 cells
exposed to 21% and 1% O2. Overall ANOVA, P 0.0001; post hoc Newman–
Keuls multiple comparison testing: *P  0.05, ***P  0.001, and ****P 
0.0001 versus 21% O2;
†P  0.05 and †††P  0.001 versus 1% O2 Con. C: ChIP
assay of STAT3 bound to a STAT3 binding site within a region of rat Epo
promoter in rMC-1 cells exposed to 21% and 1% O2. Overall ANOVA,
P  0.0001; post hoc Newman-Keuls multiple comparison testing: ***P 
0.001 versus 21% O2,
†P  0.05, and †††P  0.001 versus Con of 1% O2;
‡‡‡P  0.001 versus AG, Vab or VabAG. D: Transient transfection of Cos-7
cells with Pluc-MCS reporter gene containing 300-bp promoter region from
rat Epo gene with rat STAT3-expressing construct. Overall ANOVA, P 
0.001; post hoc Newman–Keuls multiple comparison testing: **P  0.01
versus Con of Pluc-Epo-promoter; †P  0.05 versus AG; ‡‡‡P  0.001 versus
VEGFAG. AG, AG490; Con, control; Vab, VEGF antibody. Results are
means  SEMs (n  3). Data are representative of two independent exper-
iments.with control. However, some p-STAT3 remained bound tothe Epo promoter, potentially because STAT3 activation
was not completely inhibited by AG490 and the neutral-
izing VEGF antibody. These data suggest that the bind-
ing of p-STAT3 to the Epo promoter is mediated by VEGF-
induced STAT3 activation.
We next determined whether the STAT3 binding motif
was involved in the inhibition of Epo gene transcription. A
reporter gene containing the STAT3 binding motif within
the 5= promoter of the rat Epo gene (300 to 48 from
transcriptional start site) was cotransfected with a rat
STAT3-expressing construct into Cos-7 cells for 24 hours
at 21% O2. In the last 6 hours of transfection, 20 ng/mL
VEGF was added to activate STAT3. After the incubation,
cells were lysed and assayed with a luciferase assay.
Compared with control, VEGF treatment significantly in-
hibited Epo promoter activity. Treatment with both VEGF
and AG490 restored the transcriptional activity of the Epo
promoter, whereas AG490 alone had no effect on Epo
gene transcription (Figure 8D).
Altogether, these results are consistent with our find-
ings in vivo; we postulate that hypoxia after repeated
oxygen fluctuations causes an increase in Müller cell
VEGF expression that triggers activation of STAT3, and
activated STAT3 inhibits Epo gene expression by directly
binding to and inhibiting the activity of the Epo promoter.
Discussion
ROP is a complex disease that involves genetic37 and
environmental factors, including oxygen stresses (eg, re-
peated fluctuations in oxygen and hyperoxia), inflamma-
tion, and oxidative stress.38,39 Peripheral avascular retina
and IVNV are two main features in ROP. It has long been
proposed that retinal hypoxia from avascular retina
caused by a delay in retinal vascular development and
constriction of newly developed retinal capillaries leads
to pathologic angiogenesis in ROP.40–42 Our laboratory
has been interested in the causes of avascular retina. We
have focused our studies on environmental effects of
oxygen stresses and use a relevant model18 that exposes
newborn pups to oxygen stresses similar to human pre-
term infants with severe ROP. Our studies and those from
other laboratories have shown that VEGF signaling,43,44
NADPH oxidase activation,13,36,39 and JAK2/STAT3 sig-
naling24,45 are important components in the pathologic
angiogenesis in ROP.
On the basis of previous studies that used the 50/10
OIR model, we found that repeated fluctuations in oxygen
increased retinal VEGF in association with persistent pe-
ripheral avascular retina before the development of
IVNV.21 This raised the question why increased VEGF
was unable to support ongoing physiological retinal vas-
cularization but instead caused IVNV. In this study, a
series of experiments that used the 50/10 OIR model was
performed to identify whether increased VEGF caused by
oxygen stresses affected retinal vascularization and what
the underlying molecular mechanisms were. After 14
days of repeated fluctuations in oxygen, pups had an
obvious delay in retinal vascularization, producing an
increased percentage of avascular retina compared with
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tion in retinal STAT3 but not other STATs, such as STAT1
and STAT5. We previously found that one mechanism for
increased avascular retinal area in the 50/10 OIR model
was by apoptosis.11 Therefore, we postulated that STAT-
induced apoptosis of vascular or supporting cells might
be involved in the persistence of avascular retina. We
also proposed that VEGF might be involved, because it is
an angiogenic growth factor important in retinal vascular
development,28,29 so inhibiting it might reduce vascular-
ization. However, we found the STAT3-mediated avascu-
lar retina appeared independent of apoptosis or VEGF
expression. However, Epo, an important factor in retinal
capillary stabilization,7 was reduced by STAT3 activa-
tion. It also appeared that the inhibition of Epo was
local to the retina and not because of reduced produc-
tion in liver or kidney caused by systemic inhibition of
JAK/STAT signaling.
The use of recombinant human Epo in the preterm
infant has been associated with greater severity of
ROP.46 However, it also has beneficial effects as a neu-
roprotective agent in that children who had received re-
combinant Epo as preterm infants were found to do better
on cognitive testing.34 Epo was reported to stabilize ret-
inal endothelial cells in a model of hyperoxia-induced
retinopathy,33 but in the same model, small-interfering
RNA to Epo given at a different time point reduced the
severity of later retinopathy.47 Therefore, controversy ex-
ists as to the role of Epo in prematurity and its potential
effects in ROP. To elucidate whether increased Epo, as
an angiogenic agent, can improve retinal vascularization,
exogenous recombinant Epo was given to pups raised in
the 50/10 OIR model at early ages (p2, p4, and p6) by i.p.
injection. Our results show that pups with increased Epo
had greater retinal vascularization and reduced avascu-
lar retinal area, supporting the notion that inhibition of
retinal Epo by oxygen fluctuations in the 50/10 OIR model
might be a cause of delayed retinal vascularization and,
therefore, increased avascular retina.
JAK/STAT is a major signaling pathway for a number of
growth factors and cytokines. The finding that VEGF was
increased in the 50/10 OIR model encouraged us to
determine whether VEGF-mediated STAT3 activation
would reduce Epo expression. We found evidence to
support this prediction after using a neutralizing antibody
delivered into the vitreous of pups in the 50/10 OIR
model. Further, p-STAT3 colocalized with Müller cells in
sections of retina. In cultured rMC-1 cells, we observed
VEGF-induced STAT3 phosphorylation at both the ty-
rosine705 and serine727 sites, which are critical for
STAT3 dimerization, nuclear translocation, and transcrip-
tional activity,48–50 decreased Epo gene expression
caused by hypoxia. This last observation differs from
reports in which hypoxia-induced factor-2 can up-regu-
late Epo expression31 and may indicate that hypoxia-
regulated Epo gene expression varies according to cell
type and the activation status of JAK/STAT signaling. As
a transcriptional factor, STAT3 regulates gene expression
by directly targeting the promoter of genes. In this case,
the inhibitory effect of activated STAT3 by VEGF on Epo
gene expression may require the recruitment of STAT3 tothe Epo promoter. We predicted a STAT3 binding site
located at a region in the 5= promoter of the Epo gene
(164 to 156 from transcriptional start site). We clearly
show by ChIP analysis that, in response to hypoxia,
STAT3 appears on the promoter of the Epo gene contain-
ing the predicted STAT3 binding site. Binding of STAT3 to
the Epo promoter was reduced to that of room air levels in
the presence of AG490 or neutralizing VEGF antibody.
This suggests that the binding of STAT3 to the Epo pro-
moter is induced by hypoxia, depending on VEGF, and
that activated p-STAT3 is capable of binding to the pro-
moter of the Epo gene. We further determined that the
Epo promoter activity was suppressed by and depended
on the activation of STAT3. The results together indicate
that the inhibitory effect of VEGF-mediated p-STAT3 on
Epo gene transcription directly targets the Epo promoter.
A coregulator may also be recruited to the promoter of
the Epo gene. In future studies, we will determine what
phosphorylation site(s) of STAT3 regulates its binding to
the Epo promoter and the effects on potential recruitment
of coregulators.
In summary, we demonstrate that an increase in retinal
VEGF, sufficient to lead to pathologic avascular retina
and IVNV in the 50/10 OIR model, mediated STAT3 acti-
vation and inhibited retinal Epo expression. Exogenous
Epo provided at early time points in the model, before the
development of IVNV, led to reduced avascular retina.
However, the timing for Epo treatment appears critical so
as not to increase the risk of pathologic angiogenesis, as
suggested from studies that used the mouse OIR
model49. Clinical studies have reported a reduction in
ROP severity after inhibition of VEGF bioactivity with a
neutralizing antibody.51 However, the treatment is given
late in the course of ROP, and persistent avascular retina
remains a concern. In the 50/10 OIR and mouse OIR
models, VEGF-neutralizing antibody decreased retinal
IVNV but had no significant effect on avascular ret-
ina.13,52,53 Our findings suggest that inhibiting VEGF sig-
naling alone may not be sufficient to promote retinal vas-
cularization and that other angiogenic factors, such as
Epo, may be important. However, timing appears critical,
and further study is needed to determine whether Epo
expression during vasoproliferation might lead to later
recurrences of IVNV.
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